#United States #Brisbane #Colorectal Cancer #Freenome #SimpleScreen

Freenome's Clinical Advancements in Colorectal Cancer Screening

Freenome, a pioneering company in the realm of early cancer detection, has presented promising outcomes from its extensive clinical validation study for the enhanced version of its SimpleScreen™ test, aimed at diagnosing colorectal cancer (CRC) through a blood sample. This innovative approach has successfully met all predetermined primary and secondary endpoints, showcasing a marked improvement in performance compared to earlier versions.

Key Results from the Study

The recent update to the SimpleScreen test has demonstrated impressive sensitivity rates:

• - 18.2% for detecting advanced precancerous lesions (APLs)
• - 41.9% for APLs characterized by high-grade dysplasia (HGD)
• - 80.4% for identifying CRC cases, with commendable detection of 52% of Stage I cases

These results were adjusted according to the demographic statistics from the U.S. Census, ensuring that the data accurately represented the target screening population. The test also exhibited a specificity rate of 90% for identifying individuals with no findings during colonoscopy procedures.

Colorectal cancer remains a significant health concern, being the second leading cause of cancer-related deaths in the United States. With over 50 million adults not adherent to recommended screenings, blood-based options like SimpleScreen present a vital pathway to improve screening rates among individuals who might otherwise remain untested.

Comprehensive Study Overview

The validation study involved a vast cohort of nearly 48,995 asymptomatic adults, aged between 45 and 85, all of whom were scheduled for a screening colonoscopy. Conducted across more than 200 medical sites, this study provided a solid foundation for determining the test's efficacy. Out of the participants, the analysis accounted for more than 85 individuals diagnosed with CRC, as well as 150 cases of APLs with HGD.

The enhanced sensitivity for detecting APLs—particularly those with HGD—is crucial, as these lesions have a higher likelihood of progressing to full-blown CRC if not treated. Notably, the sensitivity figures for APL and HGD presented in this study stand as the highest reported for any non-invasive blood test in a pivotal clinical study setting thus far.

Expert Insights

Dr. Aasma Shaukat, a professor of medicine at NYU Grossman School of Medicine and co-lead principal investigator of the PREEMPT CRC study, highlighted the significance of these findings: “The sensitivity for APL and APL with HGD for the updated SimpleScreen CRC test is a marked improvement, bringing us closer to rivaling the performance of certain stool-based CRC screening tests, which may enhance patient adherence.”

Freenome’s internal models predict that these advancements could potentially yield an additional 1,582 life-years gained per 100,000 individuals screened, alongside 426 fewer CRC cases and 143 fewer CRC deaths. These figures suggest an approximate 9.5% reduction in cancer incidence and mortality, showcasing the profound impact this test could have on public health.

Future Directions in Cancer Screening

This recent accomplishment marks a significant stride forward in Freenome’s mission to innovate blood-based cancer screening methodologies. As part of this initiative, the company has submitted its Premarket Approval (PMA) application for the earlier iteration of the SimpleScreen test to the U.S. FDA. Anticipated for mid-2026 review completion, Freenome plans to submit a supplemental PMA for the newly revised test, building on the momentum generated by these impressive trial results.

Furthermore, Freenome has collaborated with Abbott through a commercial agreement to launch SimpleScreen CRC upon securing FDA approval. This partnership underscores a commitment to providing a combined multi-cancer screening product that includes not only colorectal cancer assessments but also lung cancer diagnostics tailored to patients who are eligible for both.

Jake Orville, senior vice president at Abbott’s cancer diagnostics division, expressed confidence in the results: “These findings reaffirm our belief in the potential of blood-based colorectal cancer screening to enhance the screening process.”

With the continuous expansion of screening technologies and a focus on accessible, non-invasive methods, Freenome is resolutely positioned to play a transformative role in the early detection and prevention of colorectal cancer, aiming to ensure that more individuals receive timely testing and treatment.

About Freenome

Freenome is dedicated to revolutionizing cancer detection with innovative blood-based tests, targeting the identification of cancers in their most treatable stages. By utilizing a multiomics platform and advanced AI techniques, Freenome seeks to refine cancer screening processes, ensuring tailored diagnostics that align with various patient health profiles and conditions.

In a landscape where cancer remains a leading health threat, developments like those pioneered by Freenome serve not just as scientific achievements but as hopeful advancements in the fight against one of the most pervasive diseases of our time.